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Abstract
Background: Hereditary Fibrosing Poikiloderma (HFP) with tendon contractures, myopathy and pulmonary fibrosis
(POIKTMP [MIM 615704]) is a very recently described entity of syndromic inherited poikiloderma. Previously by using
whole exome sequencing in five families, we identified the causative gene, FAM111B (NM_198947.3), the function
of which is still unknown. Our objective in this study was to better define the specific features of POIKTMP through
a larger series of patients.
Methods: Clinical and molecular data of two families and eight independent sporadic cases, including six new
cases, were collected.
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Results: Key features consist of: (i) early-onset poikiloderma, hypotrichosis and hypohidrosis; (ii) multiple
contractures, in particular triceps surae muscle contractures; (iii) diffuse progressive muscular weakness; (iv)
pulmonary fibrosis in adulthood and (v) other features including exocrine pancreatic insufficiency, liver impairment
and growth retardation. Muscle magnetic resonance imaging was informative and showed muscle atrophy and
fatty infiltration. Histological examination of skeletal muscle revealed extensive fibroadipose tissue infiltration.
Microscopy of the skin showed a scleroderma-like aspect with fibrosis and alterations of the elastic network.
FAM111B gene analysis identified five different missense variants (two recurrent mutations were found respectively
in three and four independent families). All the mutations were predicted to localize in the trypsin-like cysteine/
serine peptidase domain of the protein. We suggest gain-of-function or dominant-negative mutations resulting in
FAM111B enzymatic activity changes.
Conclusions: HFP with tendon contractures, myopathy and pulmonary fibrosis, is a multisystemic disorder due to
autosomal dominant FAM111B mutations. Future functional studies will help in understanding the specific
pathological process of this fibrosing disorder.
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Background
Poikiloderma is a dermatologic condition characterized
by skin atrophy, telangiectasias, and variegated pig-
mentation (hypo- and hyperpigmentation). Inherited
poikiloderma is a group of rare disorders including
Rothmund-Thomson syndrome (RTS [MIM 268400]),
the eponymous Weary form of hereditary sclerosing
poikiloderma [MIM 173700], Kindler syndrome [MIM
173650], and poikiloderma with neutropenia (PN [MIM
604173]) [1–4]. A distinct autosomal dominant form of
hereditary fibrosing poikiloderma (HFP) was described in
a South African family of European-descent [5]. In this
two-generation family, five individuals were affected by
this syndrome, including poikiloderma but with the add-
itional features of muscle contractures, and progressive
pulmonary fibrosis. Clinical manifestations were poikilo-
derma, telangiectasia and pigmentary anomalies especially
on the face and sun-exposed areas from early childhood.
Muscles contractures particularly involved the ankles and
feet, and together with muscle involution caused gait dis-
turbance. Pulmonary involvement was noted during the
second decade of life; progressive dyspnoea and restrictive
impairment of lung function were linked to pulmonary fi-
brosis. We previously identified HFP with tendon contrac-
tures, myopathy, and pulmonary fibrosis (POIKTMP) as a
new clinical entity and we identified the causative muta-
tions in the FAM111B gene (NM_198947.3) by whole-
exome sequencing [6].
Here, we extend the description of the POIKTMP
phenotype through observations made in two family
cases and a series of eight sporadic cases with dominant
causative FAM111B mutations. The main features con-
sist of (i) early-onset poikiloderma, hypotrichosis, hypo-
hidrosis; (ii) muscle contractures with varus foot
deformity; (iii) progressive proximal and distal muscle
weakness and (iv) progressive pulmonary fibrosis. In
total, we identified five different missense mutations
that are predicted to localize in the functional domain of
the FAM111B protein. Histological data showed a multi-
systemic adiposis and fibrosis leading to this disorder.
Methods
Patient recruitment
All the patients were referred by their referent physi-
cians (geneticists, dermatologists, neurologists or pulmo-
nologists) either on typical clinical features and/or after
FAM111B mutation identification by whole exome se-
quencing. The five members of the South African family
F10 and individuals F1, proband F2, F3, F4 were previ-
ously reported [5, 6]. Individuals F1, proband F2, F3 and
F4 were described in the initial report as individuals F1-
II2, F2-II4, F3-II1 and F4-II1, respectively [6]. In family
F2, the affected son was born after the diagnosis of
POIKTMP in the father. Four additional cases were
identified based on typical clinical features like poikilo-
derma and contractures for individuals F5, F6 and F8,
and on lung fibrosis for individual F9. It is worth noting
that Rothmund-Thomson syndrome (RTS) was sug-
gested for almost all the patients in the first years of life
(no mutation was found in the main causative gene for
RTS, RECQL4 [MIM 603780]). Whole exome sequen-
cing was performed in individuals F6 at the Centre for
Dermatology and Genetic Medicine at the University of
Dundee and F7 at the Personalized Genomic Medicine
laboratory at Columbia University and identified a
FAM111B mutation leading to the diagnosis.
Clinical investigation and phenotype
Ethnic origin and family history information was col-
lected. We routinely analyzed parameters such as
auxology, skin examination, myopathic features and/or
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contractures, lung impairment or any other major med-
ical event as shown in Table 1.
Consent
This study was approved by the institutional review
board of the Hospital of Nantes and other contributing
institutions. Written informed consent was obtained
from each adult participant and the parents of the par-
ticipating children.
FAM111B gene identification and sequencing
As described in Mercier et al., 2013, a whole exome-
sequencing strategy applied to two independent families
of Caucasian descent, a simplex French one, F1, and a
multiplex South African one, F10, highlighted the in-
volvement of FAM111B mutations in POIKTMP [6].
More recently, we found de novo mutations in five
additional independent cases: three were revealed by
either high-throughput (with a minimal 100× read
depth), and/or Sanger sequencing targeting FAM111B,
and the two others were identified by whole-exome se-
quencing. In each family, parents’ samples were ana-
lysed for screening of the familial mutation when
available, which enabled confirmation of the de novo
nature of the variant encountered (Table 1). Besides,
the absence of the FAM111B variants observed in
POIKTMP patients was checked by Sanger sequencing
in 388 healthy controls from different ethnic origins




Fifteen patients belonging to 10 independent families
were diagnosed with POIKTMP (Table 1). A mutation in
the FAM111B gene was identified in all the patients
tested. Six were females and nine were males. They were
of French, Algerian, Irish, Italian, Moroccan, Dominican
Republic and South-African origins. The median age at
last follow-up was 20.5 years (min = 8 months; max =
56 years).
Poikiloderma and ectodermal abnormalities
Skin abnormalities were the earliest findings in all pa-
tients. Poikiloderma appeared during early infancy, typ-
ically in the first six months of age. It was mainly
localized to the face (Fig. 1). Transient exacerbations of
facial erythema were seen following sun exposure. This
erythema was complicated by bullous lesions in individ-
ual F1. Hyperpigmented and hypopigmented lesions are
a constituent part of poikiloderma but individual F5 also
had Blaschko linear hyperpigmentation (Fig. 2b).
Sparse scalp hair, sparse or absent eyelashes and/or
eyebrows was found in all patients with variable severity.
Hair dysplasia and leukoplakia were not observed (Fig. 2).
Three patients had nail dysplasia. Hypohidrosis with
heat intolerance was observed in most of the patients
(11/12).
In addition, seven patients had lymphoedema of lower
and/or upper extremities that was complicated by cellu-
litis in three of them (Fig. 2g). Chronic erythematous
and scaly skin lesions described by clinicians as eczema-
like, ichthyosis-like or psoriasis-like lesions were often
observed on the limbs. Some patients had palmoplantar
erythrosis, mild palmoplantar keratoderma or sclerosis
of the digits. Of note, skin lesions in particular facial poi-
kiloderma improved with time.
Microscopic examination of the biopsied skin per-
formed in four patients revealed a very characteristic
pattern of epidermal atrophy with scleroderma-like fea-
tures and conspicuous alterations of the elastic network
in the superficial and deep dermis. Enlarged and frag-
mented elastic fibres were noted and the formation of
elastic globes in the papillary dermis was associated with
a diffuse slight collagen sclerosis (Fig. 3). Lesions could
easily be misdiagnosed as RTS lesions, as it was the case
for individual F4. In individual F6, hyperkeratosis, para-
keratosis, hypergranulosis were observed as well as
acanthosis and spongiosis with numerous apoptotic
keratinocytes.
Muscle contractures and myopathy
After cutaneous features, muscle contractures represent
the second suggestive finding of POIKTMP. These can
be seen as early as 2 years of age in some patients. The
most commonly affected muscle was the triceps surae,
leading to a shortening of Achilles tendons. Five patients
underwent surgery for Achilles tendon lengthening at
median age of 10 years (min = 5; max = 14). For example,
individual F1 had very severe varus deformities of both
feet. His gait impairment appeared at the age of 6 years
and outdoor wheelchair use was required by the age of
7 years. Following tendon lengthening surgery, he was
able to walk again. In four patients, contractures of
upper limbs (biceps brachii and carpal extensors) were
also noted. Thoracolumbar scoliosis was noticed in two
patients (proband F2 and F3).
Muscle atrophy was observed in four patients (individ-
uals F1, F3, F4 and proband F2) and in some cases, was
diffuse and severe. The South African proband had atro-
phic thenar and hypothernar eminences. Similarly, indi-
vidual F1 did not have the ability to oppose the thumb
on both hands. The majority of patients (8/11) devel-
oped a progressive weakness of both proximal and distal
muscles of all four limbs, although the first symptoms
observed in lower limbs were rather proximal. The me-
dian age of onset of muscle involvement was 5.9 years
(min = 1; max = 11). Clinical variability of muscle weakness
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Table 1 Clinical and molecular data of affected individuals affected
Characteristics Individual F1a Family F2a Individual F3a Individual F4a Individual F5
Origin: France Origin: Algeria Origin: Italy Origin: France/Morocco Origin: France
Sex M M (proband) M (son) F F F
Age at last examination 10 yrs 32 yrs 8 months 13 yrs 9 yrs 4 yrs




No 165 cm (−1.7 SD);
40 kg (BMI:14.7)
No 145 cm (−1.5 SD);
30 kg (BMI: 14.3)
120 cm (−1.9 SD);
15.8 kg (BMI:11)
102 cm (+0.2 SD);
14 kg (BMI:13.5)
Delayed puberty n/a Yes (17 yrs) n/a Yes n/a n/a
Normal IQ Yes Yes n/a Yes Yes Yes
Psychiatric disorders No No n/a No No No
Skin Poikiloderma
(early childhood)
Yes Yes Yes Yes Yes Yes
- Face Yes Yes Yes Yes Yes Yes
- Exposed area/
photosentivity
Yes Yes Yes Yes Yes Yes
- Upper and/or
lower limbs
Yes Yes No Yes Yes Yes
Bullous lesions Yes No No No No No
Eczema-like Yes Yes Yes No Yes Yes
Ichthyosis-like No No No No No Yes
Psoriasis-like No No No No Yes No
Blaschko linear hypo/
hyperpigmentation
No No No No No Yes
Lymphoedema
of extremities
Yes No No Yes Yes Yes
Cellulitis Yes No No Yes No No
Sclerosis of the digits No Yes No No No No
Palmoplantar
abnormalities





Yes Yes Yes n/a Yes Yes
Hair Hypotrichosis/Alopecia Yes Yes Yes Yes Yes Yes
- Scalp hair Yes Yes Yes Yes Yes Yes
- Eyebrows Yes Yes Yes Yes Yes Yes
- Eyelashes Yes Yes Yes Yes Yes Yes















Table 1 Clinical and molecular data of affected individuals affected (Continued)
Muscle Muscle weakness
(Age at onset)
Yes (7 yrs) Yes (11 yrs) No Yes (4y) Yes (14 months) No
- Proximal lower limbs Yes yes No Yes Yes No
- Distal lower limbs Yes Yes No Yes Yes No
- Proximal upper limbs Yes Yes No Yes Yes No




No Yes (SCM), trunk
extensors, abdominal
muscles
No n/a Yes No
Amyotrophy Yes Yes No Yes Yes No
Abolition of lower limb
tendon reflex
No (weak reflexes) Yes No Yes Yes No
Tendon lengthening
(age)
Yes (7 yrs) Yes (11 yrs) No Yes (13 yrs) No No
Joints Lower limbs contractures
(Age at onset)
Triceps surae (6 yrs) Triceps surae (7 yrs) No Triceps surae Triceps surae (2 yrs)
Hamstring (7 yrs)
Triceps surae (3 yrs)
Triceps surae muscle/
Hamstring muscle
Upper limb contractures No Biceps brachii
(2–3 yrs) Carpal
extensor
No Yes Yes No
Biceps brachii and carpal
extensors
Spine Scoliosis No Yes No Yes No No
Oral sphere Dysphagia/Velopharyngeal
insufficiency
No Yes No n/a Yes No
Liver Hepatomegaly No No No Yes No No
Pancreas Steatorrhea/Exocrine
insufficiency
Yes n/a n/a n/a No Yes
Eye Cataract No No No Yes No No
Other No No No No No No





N n/a N Eosinophilia
0.8 × 10e9/L
N
Liver function n/a N n/a Cholestasis n/a SGOT: 63 IU/L (<53);
SPGT: 56 IU/L (<36);
ALP: 308 IU/L (<335);
GGT: 53 IU/L (<26)
Muscle
exploration
EMG: myogenic Yes n/a n/a Yes Yes n/a





















Yes (asthma) Yes n/a n/a Yes n/a
- FVC (% of predicted) 1.61 L (83 %) 1.82 L (42 %) n/a n/a 38 % n/a
- FEV1 (% predicted) 1.25 L/min (73 %) 2.02 (44 %) n/a n/a n/a n/a
- FEV1/FCV (%) 78 % 111 % n/a n/a n/a n/a
- DLCO n/a 41 % n/a n/a 51 % n/a
PET/CT-scan n/a No pulmonary
fibrosis (CT scans)
n/a n/a No fibrosis n/a








n/a n/a n/a RTS-like n/a
Visceral organs n/a n/a n/a n/a n/a n/a
Vasculature n/a n/a n/a n/a n/a n/a
Gene analysis RECQL4 No mutation No mutation n/a No mutation No mutation No mutation
Other genes No CAPN3, LMNA,
CAV3 (no mutation)
No No SMN1 (no mutation) No































Table 1 Clinical and molecular data of affected individuals affected (Continued)
Characteristics Individual F6 Individual F7 Individual F8 Individual F9 Family F10a





Sex F M M M F (proband) M (father) M (brother) M (brother)
Age at last examination 5 yrs 23 yrs 8 yrs Death: 40 yrs 26 yrs Death:
56 yrs
Death: 30 yrs 31 yrs




91.3 cm (−3.9 SD);
12.3 kg (BMI:14.8)
No No 163 cm (−2.1 SD);
53 kg (BMI:19.9)
No No No No
Delayed puberty n/a No n/a No n/a n/a n/a n/a
Normal IQ Yes Yes Yes Yes Yes Yes Yes Yes
Psychiatric disorders No No No Schizophrenia No No No No
Skin Poikiloderma
(early childhood)
Yes Yes Yes Yes Yes Yes Yes Yes
- Face Yes Yes Yes Yes Yes Yes Yes Yes
- Exposed area/
photosentivity
No Yes Yes Yes Yes Yes Yes Yes
- Upper and/or
lower limbs
Yes Yes Yes No Yes Yes Yes Yes
Bullous lesions Yes No No No No No No No
Eczema-like Yes No No No No No No No
Ichthyosis-like No No No Yes
Psoriasis-like No No No No No No No No
Blaschko linear hypo/
hyperpigmentation
No Yes No No No No No No
Lymphoedema
of extremities
Yes Yes No Yes No No No No
Cellulitis Yes No No No No No No No









Yes Yes No n/a Yes Yes Yes Yes
Hair Hypotrichosis/Alopecia Yes Yes Yes Yes Yes n/a n/a Yes
- Scalp hair Yes Yes Yes Yes Yes Yes Yes Yes
- Eyebrows Yes Yes Yes Yes Yes Yes Yes Yes















Table 1 Clinical and molecular data of affected individuals affected (Continued)
Nails Dysplasia Yes Yes No No Yo No No No
Muscle Muscle weakness
(Age at onset)
Yes (infancy) Yes (2 yrs) Yes (8 yrs) No Yes (9 yrs) n/a n/a n/a
- Proximal lower limbs Yes Yes Yes No n/a n/a n/a n/a
- Distal lower limbs No Yes Yes No n/a n/a n/a n/a
- Proximal upper limbs No Yes No No n/a n/a n/a n/a




No Yes No No n/a n/a n/a n/a
Amyotrophy No No No No n/a n/a n/a n/a
Abolition of lower limb
tendon reflex
n/a Yes No No n/a n/a n/a n/a
Tendon lengthening
(age)
No No No No Yes (14 yrs) No Yes (5 yrs) No
Joints Lower limbs contractures
(Age at onset)
Triceps surae (4 yrs) No Triceps surae
(7 yrs)
No Triceps surae n/a n/a No
Triceps surae muscle/
Hamstring muscle
Upper limb contractures No Yes (identified at age 23) No No No n/a n/a No
Biceps brachii and carpal
extensors
Spine Scoliosis No No No No No No No No
Oral sphere Dysphagia/Velopharyngeal
insufficiency
No Yes No No n/a n/a n/a n/a
Liver Hepatomegaly No No No No No No No No
Pancreas Steatorrhea/Exocrine
insufficiency
Yes Yes No No n/a n/a n/a n/a
Eye Cataract No No No No No No No No
Other No Shallow orbits with mild
restriction of medial rectus
action OU; right macular
pigmentary changes
No Corneal thickness No No No No
Blood test SCK (UI/l) (maximum) N 372 n/a N n/a n/a n/a n/a
Blood count
abnormalities (maximum)
Eosinophilia 0.9 x 10e9/L PLT count: 78 x 10e9/L,
MCV: 98.4 fL
N N n/a n/a n/a n/a
Liver function SGOT:210 IU/L (<40); SGPT:
151 IU/L (<35); ALP: 772 IU/L
(<315); Bili: 33 mmol/l (<14)
SGOT: 100 IU/L (<38); SGPT:
132 IU/L (<41); ALP:129 IU/L
(<129); GGT:106 IU/L (<58)
n/a n/a n/a n/a n/a n/a
Muscle
exploration















Table 1 Clinical and molecular data of affected individuals affected (Continued)
MRI/CT-scan n/a Atrophy of paraspinal and
rectus abdominis muscles
(CT scan)






Yes Yes Yes (poor
participation)
Yes Yes Yes Yes No
- FVC (% of predicted) 53 % 64 % 1.33 L (86 %) 1.47 L (36 %) 78 % n/a 34 % 91 %
- FEV1 (% predicted) 56 % n/a 1.32 L/min
(101 %)
1.15 L/min (34 %) n/a n/a 37 % n/a
- FEV1/FCV (%) N n/a 99 % 78 % 86 % n/a 90 % 76 %
- DLCO n/a n/a 0.87 (64 %) Not feasible 67 % n/a 34 % 88 %
PET/CT-scan No fibrosis No pulmonary fibrosis;




n/a n/a n/a n/a





















Vasculature n/a n/a n/a n/a n/a n/a Elastic degeneration,
medial calcification
n/a
Gene analysis RECQL4 No mutation No mutation No mutation No mutation n/a No
mutation
No mutation n/a
Other genes No CLCN1- c.2509-3C > T
(intronic between exons
22 and 23); c.2926 C > T
(p.976 R > X, nonsense
mutation)
No No No No No No




c.1861 T > G
(p.Tyr621Asp)
n/a c.1861 T > G
(p.Tyr621Asp)
c.1861 T > G
(p.Tyr621Asp)
Inheritance De novo De novo de novo n/a Paternal
inheritance
n/a Paternal inheritance Paternal
inheritance
aIndividuals F1, proband F2, F3 and F4 were described in the initial report as individuals F1-II2, F2-II4, F3-II1 and F4-II1, respectively [6]
The following abbreviations are used: ALP alkaline phosphatase, Bili bilirubin, BMI body mass index, DLCO diffusing capacity of the lung for carbon monoxide, EMG electromyography, FEV1 forced expiratory volume,
FVC forced vital capacity, GGT gamma-glutamyl transpeptidase, MCV mean corpuscular volume, N normal, n/a not available, MRI magnetic resonance imaging, PET/CT-scan positron emission tomography/computed
tomography scan, PFT pulmonary function test, PLT platelet, RTS Rothmund-Thomson syndrome, SCK serum creatine kinase, SCM sternocleidomastoid muscle, SGOT serum glutamate oxaloacetic transaminase, SGPT















Fig. 1 Facial and scalp skin lesions. Poikiloderma and alopecia of the scalp, eyebrows, and eyelashes in individuals F1, F4, F5, F6, F8 and F9 (a-f)
Fig. 2 Skin lesions of upper and lower limbs. Eczema-like and psoriasis-like dermatosis of the upper limbs in individual F4 (a); hyperpigmentated
regions in individual F5 (b); chronic lymphoedema of lower limbs and hands in individuals F4 (c, d), F6 (e), F8 (f); diffuse skin lesions of lower
limbs and cellulitis in individual F6 (e, g)
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was high. The most severe case, individual F4, lost ambula-
tion at the age of 3 years old. At the age of 9 years she
could no longer transfer from bed to wheelchair. Her
muscle strength (MRC score) was graded globally between
2 and 3. The other individuals are still ambulatory. Of the
adult patients, proband F2 was able to walk only a few
steps before stopping and was unable to climb stairs at
31 years of age. He presented with a pronounced axial
muscle impairment especially in the abdominal belt, trunk
and neck extensors with dropped head. In contrast, muscle
strength testing did not show any weakness in the
40-year-old individual F9. However, muscle involvement
was confirmed in this individual by muscle MRI,
which showed a selective involvement of the vastus
lateralis muscles (Fig. 4). Muscle MRI was performed
in two other patients (individuals F1 and proband F2),
respectively at age 7 and 30. The older individual F2 had
more severe muscle impairment. The MRI revealed a se-
vere diffuse fatty infiltration of legs with a relative
sparing of tibialis posterior and a severe fatty infiltra-
tion of the anterior compartment of thighs with a
relative sparing of posterior compartment. Abdominal
CT scan performed in individual F7 revealed atrophy
of the paraspinal and rectus abdominis muscles.
Serum creatine kinase was either normal (in 3/8 pa-
tients) or slightly increased (5/8 patients; max = 500 IU/L).
When performed, electromyography showed a normal or
myopathic pattern.
Muscle biopsy performed in six patients revealed the
same histopathologic pattern (Fig. 3). There was exten-
sive fatty infiltration and residual muscle tissue was
composed of fragmented muscle fascicles with either
normal fibers or atrophic fibers with central nuclei. No
neuropathic features (i.e. normal ATPase pattern) or
mitochondrial network abnormalities were found on
histochemistry or immunolabelling. Western blot ana-
lysis in proband F2 showed a secondary reduction of
calpain.
Fig. 3 Muscle and skin microscopy. a-d Fatty tissue, fragmented muscle fascicles next to normal fascicles in individuals F1 (a-b) or nonspecific
myopathic changes with variation in fiber size in proband F2 (c-d) (Hematoxylin and eosin staining [H&E]; ×20 (a) and ×100 magnification (b-d)).
e-f Epidermal atrophy, scleroderma-like features with a diffuse mild collagen sclerosis (e) (individual F1; H&E; ×20 magnification); elastic dystrophy
with formation of elastic globes (arrowheads) in the papillary dermis (f) (individual F1; Weigert staining; ×150 magnification)
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Pulmonary impairment
All patients for whom pulmonary data were available
had abnormal lung function with a restrictive pulmonary
pattern. Non-invasive ventilation was considered for
proband F2 who had a severe restrictive pulmonary pat-
tern. Individual F4 had recurrent bronchitis. Progressive
interstitial pulmonary fibrosis was not observed in chil-
dren, and found in only half of the adults (3/6): individ-
ual F9 and two men from the original South African
family. Pulmonary complications were life-threatening in
some individuals, as seen in these three individuals who
died at 30, 40 and 56 years of age. Two of them died
only three or four years after the first respiratory symp-
toms such as progressive breathlessness and dry cough.
Other systemic features
Growth retardation and delayed puberty
Growth retardation and/or hypotrophy were observed in
six individuals with delayed puberty in two individuals.
Enteral feeding was required in individual F4 due to low
weight, which remained 15 kg (<−3 SD) at 6 years of
age. In this individual, IGF1 level was low at 58 μg/L
(95–240). No specific testing was performed in the other
patients to investigate this feature.
Liver involvement
Liver impairment was reported in four patients. Individ-
uals F5, F6 and F7 initially presented with mildly elevated
transaminases, alkaline phosphatises, gamma-glutamyl
transferase, and/or bilirubin, which fluctuated between
normal and abnormal for F7. Furthermore, individual F3
had hepatomegaly and cholestasis, which was treated with
ursodesoxycholic acid.
Pancreatic exocrine insufficiency
Pancreatic exocrine insufficiency was diagnosed in four
individuals (F1, F5, F6 and F7). Symptoms included fatty
stools and diarrhea, which normalized with pancreatic
enzyme supplementation. A CT scan of abdomen showed
severe pancreatic atrophy in individual F7. It is worth not-
ing that post-mortem examination of one individual of the
South African family F10 showed extensive fatty infiltra-
tion of the pancreas [5].
Ophthalmologic findings
Some ophthalmologic abnormalities were observed in
three individuals viz: cataracts in individual F3, shallow
orbits with mild restriction of medial rectus action OU
and right macular pigmentary changes in individual F7
and corneal thickness in individual F9. No other oph-
thalmologic findings were associated.
Neurodevelopment
Cognitive development and function were totally normal
in all patients. Of note, one individual (F9) had schizo-
phrenia. No other psychiatric disorders were reported.
Haematological abnormalities
Eosinophilia was observed in three patients (individ-
uals F1, F4 and F6). Individual F7 had a mild
Fig. 4 Muscle MRI (coronal images: thighs (up); calves (down); T1-weighted sequence). Diffuse bright appearance of the anterior compartment of
the thighs, particularly in the vastus lateralis muscles, and the posterior compartment of the calves in individual F1 at 7 years of age (a); more severe
stage with a relative sparing of the posterior compartment of the thighs in proband F2 at 30 years (b). Specific involvement of the vastus lateralis
muscles (asterisks) with sparing of other thigh muscles in individual F9 (c)
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thrombocytopenia and a slightly increased mean cor-
puscular volume.
Genetics
To determine the molecular basis of POIKTMP, a
whole-exome sequencing strategy was first applied to
the French family F1 and the South African F10 as de-
scribed in Mercier et al., 2013. FAM111B (NM_198947.3)
appeared as the only candidate gene in common between
the two families: c.1879A >G (p.Arg627Gly) was the
unique de novo variant found in the individual F1 and
c.1861 T >G (p.Tyr621Asp) was observed in the affected
individuals of family F10.
We identified a causative mutation in each family of
the series. The variants consist of five different mis-
sense mutations that are predicted to localize in the
trypsin-like cysteine/serine peptidase domain of the
protein (Fig. 5) and are absent from all public genetic vari-
ant databases tested (dbSNP142 (http://www.ncbi.nlm.
nih.gov/snp/); Exome Variant Server, NHLBI GO Exome
Sequencing Project (ESP), Seattle, WA (URL: http://
evs.gs.washington.edu/EVS/) [accessed on October 2015];
Exome Aggregation Consortium (ExAC), Cambridge, MA
(URL: http://exac.broadinstitute.org) [accessed on October
2015]; Genome of the Netherlands [7]) and from 388
healthy controls of different ethnic origin. Four variants
are within seven consecutive codons and encode amino
acids located in the loop of the predicted functional
domain of FAM111B: c.1861 T > G (p.Tyr621Asp),
c.1874C > A (p.Thr625Asn), c.1879A > G (p.Arg627Gly),
and c.1883G > A (p.Ser628Asn). The last variant identi-
fied in individual F9 is located upstream of the loop,
but still in the trypsin-like cysteine/serine peptidase do-
main (c.1289A > C (p.Gln430Pro)). Mutations reported in
POIKTMP are available in the LOVD variant database
dedicated to FAM111B (www.LOVD.nl/FAM111B).
Discussion
We report a series of ten families of HFP with muscle
contractures, myopathy, and pulmonary fibrosis due
to dominant mutations in the FAM111B gene. Here
we have added six new cases to the previously re-
ported cases and confirm that POIKTMP is a multi-
systemic disorder involving the processes of fibrosis
and adiposis [5, 6].
In our series, all patients had poikiloderma in early in-
fancy, which is a key feature in diagnosing this disorder.
The phenotypes presented here are distinct from other
types of hereditary poikiloderma, such as RTS, heredi-
tary sclerosing poikiloderma of Weary, Kindler syndrome
or poikiloderma with neutropenia [1–4, 8–10]. In our
cases, skin lesions improved with time whereas extracuta-
neous manifestations became more prominent. RTS is the
main differential diagnosis for POIKTMP and most pa-
tients were initially misdiagnosed as RTS in childhood.
POIKTMP and RTS share the following features: early-
onset poikiloderma, ectodermal dysplasia features (hypo-
trichosis, hypohidrosis and nail dysplasia), palmoplantar
keratoderma, growth delay, cataracts and haematological
abnormalities [1].
Fig. 5 Missense variants identified in FAM111B. Conserved amino acid sequences among mammals and cluster within a putative cysteine/serine
trypsin-like peptidase domain of FAM111B. Variant #1 [c.1289A > C (p.Gln430Pro)] identified in individual F9; variant #2 [c.1861 T > G (p.Tyr621Asp)]
in the South-African family F10; variant #3 [c.1874C > A (p.Thr625Asn)] in individual F8; variant #4 [c.1879A > G (p.Arg627Gly)] in individuals F1,
F3 and family F2; variant #5 [c.1883G > A (p.Ser628Asn) in individuals F4, F5, F6 and F7
Mercier et al. Orphanet Journal of Rare Diseases  (2015) 10:135 Page 13 of 16
Strikingly, myopathy appears to be specific to POIKTMP.
Some patients presented with early prominent joint con-
tractures, mainly in the triceps surae muscles. The severity
of these contractures could impair the gait and Achilles
tendon lengthening was performed successfully in affected
patients. The patients with muscle involvement developed
weakness in both distal and proximal leg muscles and in
some of them muscle weakness extended to the upper
limbs. Axial muscle involvement was also present, espe-
cially in the trunk extensors, neck flexors, abdominal
belt and respiratory muscles. Muscle MRI is an easy
and non-invasive procedure that can help identifying
muscle involvement. Taking into account the small
number of patients, MRI images revealed an early and
selective involvement of the vastus lateralis muscle
while posterior compartment of thighs were relatively
spared. In the legs, a prominent fatty infiltration was
observed in the posterior compartment while the tibi-
alis posterior was spared. Proximodistal and axial
muscle weakness was prominent in the lower legs with
prominent joint contractures. Selective muscle involve-
ment in muscle imaging in the context of poikiloderma
should prompt diagnostic consideration of POIKTMP.
Pulmonary fibrosis, liver and pancreatic impairment
have also only been reported in POIKTMP. Some other
findings such as congenital malformations (skeletal
anomalies, visceral malformations) and cancer predis-
position seem to be specific to RTS and are not de-
scribed in POIKTMP to date.
As shown in our series, there is variability in the clin-
ical features of POIKTMP. Some patients exhibit only
cutaneous abnormalities with or without muscle involve-
ment. We cannot predict the course of the disease and
there may be long-term complications in the six patients
who are younger than 13 years of age. Pulmonary fibro-
sis seems to affect adults only, even if a restrictive lung
pattern is detected in childhood. The clinical course of
pulmonary fibrosis may be rapidly progressive, as ob-
served in individual F9 and the proband’s brother in
family F10. Some patients only had restrictive lung func-
tion due to respiratory muscle involvement in the absence
of pulmonary fibrosis. Regular lung function testing with
monitoring of vital capacity and DLCO is recommended
in the follow-up of these patients. Exocrine pancreatic in-
sufficiency is also part of the disease. It was observed in
four individuals (F1, F5, F6 and F7) and a pancreatic fatty
infiltration was identified in the South African man on
post-mortem examination at 30 years of age.
In the literature, two articles have described pancreatic
insufficiency with fatty pancreatic degeneration in RTS-
like individuals without any mutation in the RECQL4
gene [11, 12]. Meier et al. reported in 2012 a woman
with RTS who died at the age of 42 years, after multiple
organ failure, including chronic end-stage renal disease,
exocrine pancreatic insufficiency, lung fibrosis and lethal
respiratory insufficiency due to progressive systemic
muscular atrophy [11]. Of note, an abdominal CT scan
showed fatty pancreatic degeneration responsible for the
exocrine pancreatic insufficiency. Otsu et al. described
in 2008 a 20-year-old male with exocrine pancreatic
hypofunction caused by atrophy and fatty replacement
of the pancreas [12]. In both cases, no mutation in
RECQL4 gene was found [12]. We suggest that these
two cases were probably due to mutations in FAM111B.
Another RTS-like case is highly suggestive of POIKTMP
in a female affected with epilepsy [13]. We found neuro-
logical features only in one individual (F9) who pre-
sented with schizophrenia. It is unclear if this is an
incidental association or if there is a causal link with
POIKTMP. The frequency of schizophrenia is as high as
1 % in the general population and thus no conclusion
can be made based on this single observation [14]. The
phenotypes of POIKTMP and RTS are overlapping and
the frequency of POIKTMP is probably underestimated
today. We recommend FAM111B screening in the evalu-
ation of RTS or more widely of early-onset poikiloderma
when no mutation is found in the RECQL4 gene (Küry
et al., accepted in EJHG) [15].
As previously reported, the other major features of
POIKTMP are the fatty muscle infiltration observed in
muscle and skin biopsies (Figs. 3 and 4). Histological
examination of skeletal muscle showed a partial loss of
muscle tissue associated with an extensive fibrofatty tis-
sue infiltration. There was no patent indication of denerv-
ation, necrosis, or inflammation (except for one isolated
focus of inflammatory cells in individual F2). In the skin
biopsy, the pathology studies revealed collagen sclerosis,
elastic degeneration, and the absence of fatty infiltration,
in contrast to the observation made in muscle tissue. In
addition, the post-mortem study of one affected member
of the South African family revealed a diffuse fatty infiltra-
tion and fibrosis of organs such as the lungs, oesophagus
and pancreas. Similarly, the cholestasis and hepatomegaly
observed in individual F3 could likely be related to such
histological lesions, even if we do not have the confirm-
ation of this assumption. In individuals F5 and F7, SGOT
and SGPT may be elevated in parallel with creatine kinase
as these enzymes are also found in muscle. However, the
gamma-glutamyl transferase was also elevated and is
specific to the hepatobiliary system. Liver blood tests were
also abnormal in individual F6 with normal creatine kin-
ase. These data are rather in favour of a liver impairment
as shown in individual F3. In sum, the clinical, MRI
and histological findings support a pathological process
of multisystemic fibrosis and adiposis underlying this
disorder.
FAM111B mutations were found in all the families. In
individual F7, two additional variants were identified by
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whole exome sequencing in CLCN1, the gene implicated
in Myotonia Congenita [MIM 255700]. We do not know
if the combination of these variants could be pathogenic
but the patient had no myotonia, nor myotonic dis-
charges at EMG. Within the “family with sequence simi-
larity 111” gene family, there are two members:
FAM111A and FAM111B (NM_198947.3). In the litera-
ture, one article suggests the FAM111A-FAM111B locus
to be involved in prostate cancer susceptibility [16]. Bio-
informatic tools predict the FAM111B protein to contain
a trypsin-like cysteine/serine peptidase enzymatic do-
main. This domain is 45 % homologous to the one pre-
dicted in FAM111A [MIM 615292], in which causative
mutations have been recently reported to cause the
Kenny-Caffey syndrome (KCS [MIM 127000]) and
osteocraniostenosis (OCS [MIM 602361]), two clinical
entities phenotypically distinct from POIKTMP [17]. It
is worth noting that the FAM111B mutations are also lo-
cated in the functional domain of the protein and consist
of missense dominant mutations as well. This suggests
either a gain-of-function or a dominant-negative effect.
FAM111B mRNA expression has been detected in
many tissues, including keratinocytes, skeletal myo-
cytes, adipose tissue and lung. We performed immu-
noblot analyses of tissue samples in individual F1 and
detected FAM111B in skeletal striated muscle, but
not in fibroblasts or in the control [6]. Functional
studies are ongoing to determine the still-unknown
function of FAM111B and the pathophysiological mecha-
nisms underlying this disorder. This will hopefully
lead to the identification of the pathway involved in
POIKTMP pathogenesis. Advances in this area will be
crucial to understand POIKTMP pathology with the
aim of finding a treatment in the future. It could also
be beneficial for other disorders like scleroderma or
myopathies in which fibrosis and adiposis are also.
Some genotype-phenotype correlations are apparent
from our observations. The most upstream mutation
(codon 430) was located outside the loop of the func-
tional domain and was identified in individual F9 who
had asymptomatic muscle involvement, but severe
pulmonary fibrosis in adulthood. These clinical fea-
tures are very similar to the description of the South
African adult patients whose mutation (codon 621) is
located in the loop also upstream to the other
FAM111B mutations. The mutations in codons 625,
627 and 628 were found in patients with an earlier
onset of the disease and a more severe phenotype in
terms of cutaneous, muscle and/or visceral findings.
Long-term follow-up of these patients will be helpful
in generating a more complete picture of this syn-
drome. Further case reports and case series will be
needed to confirm these preliminary genotype-phenotype
correlations. We postulate that mutations in other
regions of FAM111B might lead to phenotypes differ-
ent from POIKTMP, as observed in many other disor-
ders [18, 19].
Conclusions
In conclusion, we describe in the largest series to date the
specific features of POIKTMP: early-onset poikiloderma,
ectodermal dysplasia features, muscle contractures, myop-
athy, pulmonary fibrosis, as well as growth retardation,
liver impairment, exocrine pancreatic insufficiency, cata-
racts and haematological abnormalities. An obscure
process leading to adiposis and fibrosis is responsible for
this multisystemic disorder due to FAM111B dominant
mutations. Functional studies are ongoing to understand
the pathological process in POIKTMP, which could also
be beneficial for the understanding of other fibrotic
disorders.
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